Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1601-1610 Newer>

The Motley Fool December 10, 2004 Rich Duprey	Regulators Quarantine Chiron The FDA sends a warning letter on the heels of a suspension extension by British authorities. Whether shares of the pharmaceutical ultimately finish up or down, the one-two punch from U.S. and British authorities still points to an ailing company.
The Motley Fool December 10, 2004 Brian Gorman	Cardinal Picks a Lilly Cardinal Health's deal with Lilly suggests the new fee-for-service model is gaining traction.
BusinessWeek December 20, 2004 Amy Barrett	J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant.
ifeminists December 8, 2004 Wendy McElroy	NYC Must Come Clean on Foster Kids AIDS Scandal Power without accountability is an invitation for abuse. Nothing short of transparency on the part of New York City's Administration for Child Services and drug companies, such as Glaxo SmithKline, will make the hideous accusations raised by the BBC's documentary "Guinea Pig Kids" go away.
The Motley Fool December 8, 2004 Alyce Lomax	Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days.
The Motley Fool December 8, 2004 Dave Marino-Nachison	J&J Guided to Guidant? Medical device investors felt their hearts skip as executives told The New York Times the two companies may be set to merge.
National Real Estate Investor December 1, 2004 Matt Hudgins	Pain Relief for Hospitals Hospital systems are anxious to get out of the landlord business as increasing liability insurance costs and reduced Medicare and Medicaid payments put the squeeze on capital budgets.
The Motley Fool December 7, 2004 Charly Travers	Spin the Medicine Bottle Is a new MS drug going to be a top seller or a bottom-dweller? Here's how to find out. Before investing in any pharmaceutical company with a product in development, go through this exercise to estimate the new drug's potential.
The Motley Fool December 7, 2004 Brian Gorman	ID Biomedical's Shot in the Arm The company appears well-positioned for the coming years, but it may be best to stay cautious on the company.
The Motley Fool December 7, 2004 Lawrence Meyers	Investing in Your Kid's Doctor The health-care industry can be the source of big payoffs for investors. People looking to profit from the industry other than by buying stocks like Amgen, Pfizer, or Wellpoint may want to consider Pediatrix at lower prices.
<Older 1601-1610 Newer> Return to current articles.